Targeting glia to control clinical pain: An idea whose time has come

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 1, 2004, Pages 83-88

  Watkins, Linda R ^a   Maier, Steven F ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; FLUOROCITRIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; KRONOS; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROPENTOFYLLINE; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL FUNCTION; CHRONIC PAIN; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; FOOD DRUG INTERACTION; GLIA CELL; HUMAN; NOCICEPTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; RECEPTOR BLOCKING;

EID: 13444271955     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.010     Document Type: Review

References (36)

1. L.R. Watkins S.F. Maier Beyond neurons: Evidence that immune and glial cells contribute to pathological pain states Physiol. Rev. 82 2002 981-1011
2. K.M. Foley Opioids and chronic neuropathic pain N. Engl. J. Med. 348 2003 1279-1281
3. L.R. Watkins et al. Spinal cord glia: New players in pain Pain 93 2001 201-205
4. A. Araque et al. Tripartitie synapses: Glia, the unacknowledged partner Trends Neurosci. 22 1999 208-215
5. G.W. Kreutzberg Microglia: A sensor for pathological events in the CNS Trends Neurosci. 19 1996 312-318
6. J.L. Ridet et al. Reactive astrocytes: Cellular and molecular cues to biological function Trends Neurosci. 20 1997 570-577
7. L.R. Watkins et al. Glial activation: A driving force for pathological pain Trends Neurosci. 24 2001 450-455
8. J.A. DeLeo R.W. Colburn Proinflammatory cytokines and glial cells: Their role in neuropathic pain. In Cytokines and Pain (L. Watkins ed) 1999 Birkhauser 159-182
9. J.A. DeLeo R.P. Yezierski The role of neuroinflammation and neuroimmune activation in persistent pain Pain 90 2001 1-6
10. V. Raghavendra et al. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy J. Pharmacol. Exp. Ther. 306 2003 624-630
11. S.T. Meller et al. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat Neuropharmacology 33 1994 1471-1478
12. C.J. Garrison et al. GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801 Exp. Neurol. 129 1994 237-243
13. C.J. Garrison et al. Staining of glial fibrillary acidic protein (GFAP). in lumbar spinal cord increases following a sciatic nerve constriction injury Brain Res. 565 1991 1-7
14. W.D.J. Willis Hyperalgesia and Allodynia 1992 Raven Press
15. L.R. Watkins et al. Immune and glial involvement in physiological and pathological exaggerated pain states. In Advances in Pain Research and Therapy (.In Advances in Pain Research and Therapy (Dostrovsky J.O., In Advance in Pain Research and Therapy (Carr D.B. Koltzenberg M. eds.) 2003 IASP Press 369-385
16. L.R. Watkins S.F. Maier Glia: A novel drug discovery target for clinical pain Nat. Rev. Drug Discov. 2 2003 973-985
17. E.D. Milligan et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines J. Neurosci. 21 2001 2808-2819
18. E.D. Milligan et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain J. Neurosci. 23 2003 1026-1040
19. J. Berg-Johnsen et al. Changes in evoked potentials and amino acid content during fluorocitrate action studied in rat hippocampal cortex Exp. Brain Res. 96 1993 241-246
20. S.M. Sweitzer et al. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain Neuroscience 103 2001 529-539
21. T.M. Laughlin et al. Cytokine involvement in dynorphin-induced allodynia Pain 84 2000 159-167
22. S.M. Sweitzer et al. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain J. Pharmacol. Exp. Ther. 297 2001 1210-1217
23. A. George et al. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin Pain 88 2000 267-275
24. J. Prager et al. Open label clinical experience of thalidomide in the treatment of complex regional pain syndrome Type 1 Suppl. J. Pain 4 2003 68
25. H. Mujagic et al. Mechanisms of action and potential therapeutic uses of thalidomide Croat. Med. J. 43 2002 274-285
26. K.W. Moore et al. Interleukin-10 and the interleukin-10 receptor Annu. Rev. Immunol. 19 2001 683-765
27. K. Strle et al. Interleukin-10 in the brain Crit. Rev. Immunol. 21 2001 427-449
28. C.A. Dinarello Overview of inflammatory cytokines and their role in pain In Cytokines and Pain (.In Cytokines and Pain (L.R. Watkins S.F. Maier eds.) 1999 Birkhauser Verlag 1-19
29. E.D. Milligan et al. Systemic administration of CNI-1493, a p38 MAP kinase inhibitor, blocks HIV-1 gp120-induced enhanced pain states in rats J. Pain 2 2001 326-333
30. C.I. Svensson et al. Activation of p38 MAP kinase in spinal microglia is a critical link in inflammation induced spinal pain processing J. Neurochem. 86 2003 1534-1544
31. C.I. Svensson et al. Spinal p38 MAP kinase is necessary for NMDA induced spinal PGE2 release and thermal hyperalgesia Neuroreport 14 2003 1153-1157
32. S.Y. Kim et al. Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury Neuroreport 13 2002 2483-2486
33. M. Schafers et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons J. Neurosci. 23 2003 2517-2521
34. A. Ledeboer et al. Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE J. Neuroimmunol. 136 2003 94-103
35. B.L. Davidson X.O. Breakefield Viral vectors for gene delivery to the nervous system Nat. Rev. Neurosci. 4 2003 353-364
36. R.M. Bluthe et al. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behavior: A study with interleukin-1 type I receptor-deficient mice Eur. J. Neurosci. 12 2000 4447-4456